News

Uppsala 2ndJuny 2019

 

Nanexa has filed a new patent application

Nanexa strengthens its patent portfolio with another patent application within the field of the Company’s drug delivery platform PharmaShell®. The application was submitted to the UK Patent Office on June 28, 2019. Within the priority year the Company has the opportunity to follow up the UK patent application with an international patent application (PCT application), which also Nanexa intends to do. 

CEO David Westberg comments:

Nanexa’s development work has once again resulted in an invention that we consider to be patentable. With this patent application, we further strengthen our patent portfolio around PharmaShell®, which is something I believe is very positive and also important for our business.

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.